Antipsychotic to Treat Psychosis Syndrome

Central South University300 enrolled

Overview

This study assess the safety and effects of atypical antipsychotics in subjects with psychosis syndrome and psychosis risk syndrome.

The investigators investigated whether administration of atypical antipsychotics could alleviate prodromal symptoms and be well tolerated by subjects with psychosis syndrome and psychosis risk syndrome.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

300

Conditions

Psychotic Disorders

Interventions

risperidoneDRUG

Risperdal tablets

olanzapineDRUG

olanzapine tablets

QuetiapineDRUG

quetiapine tablets

Aripiprazole

Eligibility

Sex: ALLMin age: 16 YearsMax age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: * were help-seeking young individuals in outpatients service * aged 16-30 years * fitted one of the following Criteria: Psychosis-risk Syndromes (COPS-SIPS) or Psychotic Syndrome (POPS-SIPS) or DSM-IV diagnosis of schizophreniform disorder Exclusion Criteria: * a previous diagnosis of any psychotic disorder or bipolar disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; * symptoms fully accounted for by an Axis 1 disorder or sequelae of drug/alcohol use; * neurological disorders or organic disorders affecting the central nervous system, substance-related disorders or mental retardation as defined by the DSM-IV criteria; * history treatment of antipsychotic or antidepression, mood stabilizers or electroconvulsive therapy; * diagnosed as having a serious and unstable medical condition.

Locations (1)

the Second Xiangya Hospital

Changsha, Hunan, China

RECRUITING

Outcomes

Primary Outcomes

Changes of PANSS total scores from baseline to 18 months

Time frame: 18 months

Secondary Outcomes

Social function

Social function was assessed by the Global Assessment of Functioning (GAF) every three month

Time frame: 18 months

Number of Participants with Adverse Events as a Measure of Safety and Tolerability

Adverse Events were assessed at baseline and every month after treatments

Time frame: 18 months

Central Contacts

xiaofeng Guo, Dr.

CONTACT

073185554052 fengcsu@yahoo.com.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.